# Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

> **NCT06414681** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Myelofibrosis，MF

## Interventions

- **DRUG:** Tagraxofusp
- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT06414681
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414681, "Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06414681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*